Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.

about

Emerging Molecular Technologies in Genitourinary Tumors

P2860

Q58693931-5BAE8675-F41F-4EBF-B212-EC15F83A64EB

P2860

Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.

Item

http://www.wikidata.org/entity/Q47261543

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Concordance study of PD-L1 exp ...... antibodies and RNA expression.

@en

Concordance study of PD-L1 exp ...... antibodies and RNA expression.

@nl

type

Item

label

Concordance study of PD-L1 exp ...... antibodies and RNA expression.

@en

Concordance study of PD-L1 exp ...... antibodies and RNA expression.

@nl

prefLabel

Concordance study of PD-L1 exp ...... antibodies and RNA expression.

@en

Concordance study of PD-L1 exp ...... antibodies and RNA expression.

@nl

P1476

Concordance study of PD-L1 exp ...... antibodies and RNA expression.

@en

P2093

Allen Gown

http://www.w3.org/2001/XMLSchema#string

Cigdem Ussakli

http://www.w3.org/2001/XMLSchema#string

Maria Tretiakova

http://www.w3.org/2001/XMLSchema#string

Masha Kocherginsky

http://www.w3.org/2001/XMLSchema#string

Regan Fulton

http://www.w3.org/2001/XMLSchema#string

Tatjana Antic

http://www.w3.org/2001/XMLSchema#string

Thomas Long

http://www.w3.org/2001/XMLSchema#string

P2860

PD-L1 expression in human cancers and its association with clinical outcomes

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.

P2888

modpathol.2017.188

P31

scholarly article

P356

10.1038/MODPATHOL.2017.188

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1099916236

http://www.w3.org/2001/XMLSchema#string

P698

29271413

http://www.w3.org/2001/XMLSchema#string

Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.

about

P2860

P2860

Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P6179

P698